Replimune Group, Inc. filed a Form 8-K to disclose that it will attend a meeting with the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee on July 30, 2026. The company intends to discuss its Biologics License Application resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma. Replimune has made available presentation slides as Exhibit 99.1. This regulatory engagement is material as it addresses the status of a key drug candidate seeking approval for a serious, life-threatening disease where current treatment options are limited. The company operates in the biotechnology industry and develops immunotherapies for cancer.
